Int J Curr Pharm Res, Vol 9, Issue 3, 58-61Original Article



Department of Pharmacy, Shri G. S Institute of Technology and Science, 23-Park Road, Indore (MP) India 452003

Received: 28 Dec 2016, Revised and Accepted: 20 Mar 2017


Objective: Current therapies to treat P. falciparum malaria are heavily reliant on artemisinin-based combinations. However, resistance to artemisinin has recently been identified, and resistance to key artemisinin partner drugs is already widespread. Therefore, there is an urgent need for new antimalarial drugs with improved attributes over older therapies. The objective of this research work is to synthesize new antimalarial agents more effective against clinically relevant malarial strains.

Methods: In present work, a series of ten 3-phenyl-2-thioxothiazolidin-4-one (MF1-MF10) derivatives, were synthesized by Knoevenagel condensation of N-phenyl rhodanine (I1) with substituted aromatic or hetro aromatic aldehydes using microwave irradiation. N-phenyl rhodanine (I1) was synthesized by a conventional reaction involving methyl-2-mercaptoacetate (1) and phenyl Isothiocyanates in presence of triethylamine. All the synthesized compounds were characterized by various spectroscopic techniques and evaluated for in-vitro antimalarial activity by microdilution technique against resistance strains of Plasmodium falciparum.

Results: The antimalarial activity data showed that six compounds (MF1, MF3, MF4, MF5, MF7 and MF8) exhibited IC50 values ranging from 1.0-1.30 µg/ml, three compounds (MF2, MF6 and MF10) displayed IC50 values in the range of 0.9-1.0 µg/ml. Compound MF9 showed most significant result with maximum activity (IC50 = 0.85µg/ml).

Conclusion: The antimalarial activity results revealed that compound MF9 possess potent activity and could be identified as a promising lead for further investigation.

Keywords: P. falciparum, 3-phenyl-2-thioxothiazolidin-4-one, Antimalarial activity


Malaria remains one of the most important infectious disease problems in the world, accounting for an estimated 212 million cases and up to 429 000 deaths in 2015. Malaria is caused by five species of parasites belonging to the genus Plasmodium. Four of these, P. falciparum, P. vivax, P. malariae and P. ovale–are human malaria species that are spread from one person to another via the bite of female mosquitoes of the genus Anopheles. [1] Plasmodium falciparum is the most lethal protozoan parasite of the genus, which is responsible for malaria complications such as cerebral malaria or severe anaemia. [2, 3] At present, no effective vaccines are available due to the high mutability of the genome of P. falciparum,[4] meanwhile, resistance of malaria parasites has also quickly developed to a variety of quinoline analogs (e. g., chloroquine), antifolates (e. g., sulfadoxine-pyrimethamine) and inhibitors of electron transport (e. g.,atovaquone). What’s worse, resistance to artemisinin has now emerged [5, 6]. Accordingly, the discovery of new effective drugs to counter the spread of malaria parasites that are resistant to existing agents, especially acting on multi-targets, is an urgent need. The development of drug resistance has become a major health concern and has stimulated the search for alternative antimalarial agents. In this perspective rhodanine nucleus offers an alternative due to presence of wide spectrum of activities such as antibacterial [7], anti-inflammatory [8], antiviral [9, 10], antidiabetic [11], anticancer [12], tyrosinase inhibitors [8] and antimalarial [13] and are frequently associated with low toxicity and they can be considered as a privileged scaffold and an ideal framework for the design of compounds that can interact with different targets as their inherent affinity for several biological targets [14]. In present work, a series of ten new 3-phenyl-2-thioxothiazolidin-4-one (MF1-MF10) derivatives were synthesized and evaluated for their in-vitro antimalarial activities against resistant strain of Plasmodium falciparum. Herein synthesis and antimalarial activity of some new 3-phenyl-2-thioxothiazolidin-4-one derivatives is reported.


Melting points were determined by the open capillary method and are uncorrected. The progress of the reactions was monitored by thin layer chromatography (TLC) with ethyl acetate: hexane (1:1 v/v) as eluent. TLC was carried out on precoated plates (silica gel 60, F254) and visualized with UV light. Column chromatography was performed on silica gel (100-200). Anton Paar, Monowave 300, Microwave Synthesis Reactor was used for microwave-assisted synthesis. Infrared spectra were determined as KBr pellets on a Shimadzu IR affinity-1 model 1400 spectrophotometer and are expressed in cm–1. 1H NMR spectra were recorded on a Bruker’s Avance-III FT NMR spectrometers using CDCl3 as a solvent; chemical shifts are expressed in δ (ppm). HRMS spectral data were obtained with a Bruker micro, TOF QII high-resolution mass spectrometer and both the above analysis were performed at Indian Institute of science and research technology (IISER, Bhopal); IR analyses were performed in Department of Pharmacy, S. G. S. I. T. S., Indore M. P.

General method for synthesis of N-phenyl Rhodanine [15]

A mixture of phenyl isothiocyanate (0.11 mmol), methyl-2-mercaptoacetate (0.1 mmol) and Et3N (0.03 mmol) in CH2Cl2 was stirred for 1 hour. Excess isothiocyanate was removed by amino-methylated polystyrene resin (0.015 mmol). The solution was filtered and concentrated to give N-phenyl rhodanine (I1).

General method for Synthesis of MF1-MF10

A mixture of N-phenyl rhodanine (I1) (0.2 mmol,), substituted aromatic/heteroaromatic aldehydes (0.2 mmol), and three drops of piperidine in absolute ethanol (5 ml) were thoroughly mixed in a glass vial (G10/G30). The reaction mixture was then heated with microwave irradiation at 100 °C for 25 min (table 1). After cooling, the solid mass was placed in 50 ml of cold ethanol and crushed ice. The slurry was filtered to give solid mass and dried under vaccum to give corresponding MF1 to MF10 derivatives.

Table 1: Experiment setting and method for microwave assisted synthesis

Step Program Temperature Time Cooling Stirrer Speed
°C mm: ss Rpm
Heat as fast as possible 100 - Off 600
Hold - 25:00 Off 600
Cool down 55 0 On 600

(Z)-5-benzylidene-3-phenyl-2-thioxothiazolidin-4-one (MF1)

Yellow crystal; IR (KBr) cm-1; 3064.06 (=C-H, stretch), 2926.14 (C-H, stretch, aromatic), 1673.32 (C=O), 1611.59 (C=S), 1370.48 (C=C, aromatic), 842.93 (C-H, bend, aromatic); 1H NMR (CDCl3): 7.98 (s, 1H, =CH), 7.53 (d, 2H, N-Phenyl), 7.49 (d, 2H, Phenyl), 7.46 (t, 2H, N-Phenyl), 7.43 (t, 2H, Phenyl), 7.34 (t, 1H, N-Phenyl), 7.25 (t, 1H, Phenyl); HRMS (ESI+) (m/z): [M+1], 298.

(Z)-5-(4-chlorobenzylidene)-3-phenyl-2-thioxothiazolidin-4-one (MF2)

Yellow crystal; IR (KBr) cm-1; 3017.76 (=C-H, stretch), 2923.25 (C-H, stretch, aromatic), 1716.72 (C=O), 1599.06 (C=S), 1490.07 (C=C, aromatic), 838.11 (C-H, bend, aromatic), 747.45 (C-Cl); 1H NMR (CDCl3): 7.65 (s, 1H, =CH), 7.54 (d, 2H, Chloro phenyl), 7.49 (d, 2H, N-Phenyl), 7.43 (d, 2H, Chloro phenyl), 7.26 (t, 3H, N-Phenyl); HRMS (ESI+) (m/z): [M+], 332.

(Z)-5-(4-bromobenzylidene)-3-phenyl-2-thioxothiazolidin-4-one (MF3)

Yellow crystal; IR (KBr) cm-1; 3030.3 (=C-H, stretch), 2938.68 (C-H, stretch, aromatic), 1714.79 (C=O), 1594.23 (C=S), 1509.36 (C=C, aromatic), 832.32 (C-H, bend, aromatic), 737.8 (C-Br); 1H NMR (CDCl3): 7.92 (s, 1H, =CH), 7.55 (d, 1H, N-Phenyl), 7.49 (d, 2H, bromo phenyl), 7.33 (d, 2H, bromo phenyl), 7.31 (d, 1H, N-Phenyl), 7.25 (t, 3H, N-Phenyl); HRMS (ESI+) (m/z): [M+], 316.

(E)-5-((1H-pyrrol-2-yl)methylene)-3-phenyl-2-thioxothiazolidin -4-one (MF4)

Yellow crystal; IR (KBr) cm-1; 3337.96 (N-H, Pyrrole) 3027.41 (=C-H, stretch), 1689.72 (C=O), 1601.95 (C=S), 1495.86 (C=C, aromatic), 814 (C-H, bend, aromatic); 1H NMR (CDCl3): 8.90 (s, 1H, NH-pyrrole), 7.76 (s, 1H, =CH), 7.47 (t, 3H, N-Phenyl), 7.27 (d, 2H, N-Phenyl), 7.24 (d, 2H, Pyrrole), 6.45 (t, 1H, Pyrrole); HRMS (ESI+) (m/z): [M+1]: 287.

(E)-5-((1H-indol-2-yl)methylene)-3-phenyl-2-thioxothiazolidin-4-one (MF5)

Yellow crystal; IR (KBr) cm-1; 3280.80 (N-H, Indole), 3057.30 (=C-H, stretch), 3014.87 (C-H, stretch, aromatic), 1678.14 (C=O), 1590.38 (C=S), 1515.15 (C=C, aromatic), 829.43 (C-H, bend, aromatic), 1235.46 (C-N);1H NMR (CDCl3): 8.83 (s, 1H, NH-Indole), 8.16 (s, 1H, =CH), 7.57 (d, 2H, N-phenyl), 7.51 (t, 3H, N-phenyl), 7.44 (d, 2H, Indole), 7.29 (t, 2H, Indole); HRMS (ESI+) (m/z): [M+1], 337

(Z)-5-(3-nitrobenzylidene)-3-phenyl-2-thioxothiazolidin-4-one (MF6)

Yellow crystal; IR (KBr) cm-1; 3060.20 (=C-H, stretch), 3014.87 (C-H, stretch, aromatic), 1726.36 (C=O), 1604.84 (C=S), 1537.33 (C=C, aromatic), 823.64 (C-H, bend, aromatic), 1379.16 (-NO2); 1H NMR (CDCl3): 8.39 (s, 1H, NO2-phenyl), 8.28 (d, 1H, NO2-phenyl), 7.82 (d, 1H, NO2-phenyl), 7.79 (s, 1H, =CH), 7.68 (t, 1H, NO2-phenyl), 7.26-7.34 (d, 2H, N-Phenyl), 7.49-7.57 (t, 3H, N-Phenyl); HRMS (ESI+) (m/z): [M+1], 343

(E)-3-phenyl-5-(thiophen-2-ylmethylene)-2-thioxothiazolidin-4-one (MF7)

Orange crystal; IR (KBr) cm-1; 3084.31 (=C-H, stretch), 3019.69 (C-H, stretch, aromatic), 1709.97 (C=O), 1590.38 (C=S), 1496.83 (C=C, aromatic), 842.93 (C-H, bend, aromatic); 1H NMR (CDCl3): 7.95 (s, 1H, =CH), 7.72 (d, 1H, Thiophen), 7.56 (t, 1H, Thiophen), 7.50 (t, 3H, N-Phenyl), 7.54 (t, 1H, N-Phenyl), 7.44 (d, 2H, N-Phenyl),; HRMS (ESI+) (m/z): [M+1], 304

(Z)-3-phenyl-5-(pyridin-2-ylmethylene)-2-thioxothiazolidin-4-one (MF8)

Yellow crystal; IR (KBr) cm-1; 3044.77 (=C-H, stretch), 2932.54 (C-H, stretch, aromatic), 1710.93 (C=O), 1607.74 (C=S), 1495.86 (C=C, aromatic), 781.20 (C-H, bend, aromatic), 1675.21 (C=N); 1H NMR (CDCl3): 8.79 (d, 2H, Pyridine), 7.75 (d, 2H, N-Phenyl), 7.67 (s, 1H, =CH), 7.54 (t, 2H, Pyridine), 7.47 (t, 3H, N-Phenyl); HRMS (ESI+) (m/z): [M+1], 299.

(Z)-3-phenyl-5-(pyridin-4-ylmethylene)-2-thioxothiazolidin-4-one (MF9)

Orange crystal; IR (KBr) cm-1; 3070.81 (=C-H, stretch), 3016.8 (C-H, stretch, aromatic), 1718.85 (C=O), 1592.31 (C=S), 1543.12 (C=C, aromatic), 807.24 (C-H, bend, aromatic), 1693.57 (C=N); 1H NMR (CDCl3): 8.76 (d, 2H, Pyridine), 7.66 (s, 1H, =CH), 7.36 (d, 2H, Pyridine), 7.51 (t, 3H, N-Phenyl), 7.27 (d, 2H, N-Phenyl); HRMS (ESI+) (m/z): [M+1], 299.

(Z)-5-(4-(dimethylamino)benzylidene)-3-phenyl-2-thioxothiazolidin -4-one (MF10)

Orange crystal; IR (KBr) cm-1; 3083.34 (=C-H, stretch), 2924.21 (C-H, stretch, aromatic), 1735.04 (C=O), 1684.89 (C=S), 1583.63 (C=C, aromatic), 841 (C-H, bend, aromatic); 1H NMR (CDCl3): 7.89 (s, 1H, =CH), 7.47 (d, 2H, N-Phenyl), 7.43 (t, 3H, N-Phenyl), 7.32 (d, 2H, Phenyl), 7.24 (d, 2H, Phenyl), 3.06 (s, 6H CH3); HRMS (ESI+) (m/z): [M+1] 341.

Invitro antimalarial evaluation

Assay protocol

All the synthesized compounds were screened for in vitro antimalarial activity at Microcare laboratory and TRC, Surat, Gujarat. The in vitro antimalarial assay was carried out in 96 well microtiter plates according to the microassay protocol of Rieckmann and co-workers with minor modifications. All the cultures of P. falciparum strains were maintained in medium RPMI1640 supplemented with 25m MHEPES, 1% D-glucose, 0.23% sodium bicarbonate and 10% heat-inactivated human serum. The asynchronous parasites of P. falciparum were synchronized after 5% D-sorbitol treatment to obtain only the ring stage parasitized cells. For carrying out the assay, an initial ring stage parasitaemia of 0.8 to 1.5% at 3% haematocrit in a total volume of 200 µl of medium RPMI-1640 was determined by samples, prepared in DMSO and their subsequent dilutions were prepared with culture Jaswant Singh Bhattacharya (JSB) staining to assess the percent parasitaemia (rings) and maintained with 50 % RBCs (O+). A stock solution of 5 mg/ml of each of the test samples was prepared in DMSO and subsequent dilutions were prepared with culture medium, then diluted samples were added to the test wells so as to obtain final concentrations ranging between 0.4µg/ml-100µg/ml in duplicate well-containing parasite cell preparation. The culture plates were incubated at 37 °C in a candle jar, after 36-40 h of incubation; thin blood smear slides were prepared from each well and stained with JSB stain. The slides were observed under a microscope to record maturation of ring stage parasites into trophozoites and schizonts in presence of different concentrations of the test agents. The test concentration which inhibited the complete maturation into schizonts was recorded as the IC50 value of test compounds.



The 3-phenyl-2-thioxothiazolidin-4-one (MF1-MF10) derivatives describe in present research work are shown in table 2. N-Phenyl Rhodanine (1) was synthesized by reacting methyl thioglycolate with phenyl isothiocyanate at room temperature as outlined in scheme 1.

The intermediates 1 upon Knoevenagel condensation with suitably substituted aromatic/hetro aromatic aldehydes under microwave heating condition in presence of piperidine produced 3-phenyl-2-thioxothiazolidin-4-one (MF1-MF10) derivatives. This reaction generated a double bond that produced E and Z isomers. Similar analogs are reported to exist predominantly as Z-isomers. [8, 16] it is presumed that the derivatives synthesised here are mainly Z-isomers.

Methyl-2-mercaptoacetate (1) N-Phenyl Rhodanine (I1) MF1-MF10

Scheme 1: Reagents and Conditions (i) Phenyl Isothiocynates, TEA, CH2Cl2, rt, 1h; (ii) Piperidine, ethanol, MW,100 °C, 25 Min

Table 2: Structure, molecular formula, molecular weight, % yield, melting point and antimalarial activity (IC50µg/ml) of MF1-F10 derivatives

Comp.code SubstituentAr Molecular Formula Molecular Weight Melting Point °C % yield IC50µg/ml
MF1 C16H11NOS2 297.39 200-202 78 1.16
MF2 C16H10ClNOS2 331.84 160-162 80 0.90
MF3 C16H10FNOS2 315.39 180-182 80 1.28
MF4 C14H10N2OS2 286.37 240-242 76 1.14
MF5 C18H12N2OS2 336.43 220-222 82 1.22
MF6 C16H10N2O3S2 342.39 206-208 75 0.98
MF7 C14H9NOS3 303.42 226-228 78 1.06
MF8 C15H10N2OS2 298.38 224-226 80 1.15
MF9 C15H10N2OS2 298.38 194-196 80 0.85
MF10 C18H16N2OS2 340.46 234-236 82 0.94
CQ - - - - - 0.020
Quinine - - - - - 0.268

Antimalarial activity

All the compounds were screened for intra-erythrocytic in vitro antimalarial activity against resistance strains of Plasmodium falciparum by using chloroquine and quinine as reference drugs. The results of antimalarial activity are summarised in table 2. Among the ten evaluated compounds, six compounds exhibited IC50 values ranging from 1.0-1.30 (MF1, MF3, MF4, MF5, MF7, MF8), three compounds displayed IC50 values in the range of 0.9-1.0 (MF1, MF6, MF10). The compound MF9 showed the most significant result with maximum activity (IC50 = 0.85µg/ml). Variations of the different substituent on the aromatic ring and replacement of aromatic ring with heterocyclic ring have been explored to ascertain the structure-activity relationship among the synthesised compounds. With reference to the compound MF1 (IC50: 1.16 µg/ml) substitution with chloro (compound MF2, IC50: 0.9 µg/ml) or N, N, dimethyl (compound MF10, IC50: 0.94µg/ml) at para position of phenyl ring appeared to potentiate antimalarial activity while fluoro (compound MF3, IC50: 1.28 µg/ml) appeared to marginal reduction in activity. Compounds with 3-nitro (compound MF6, IC50: 0.76 µg/ml) substitutions on phenyl ring leads to a marginal increase in potency compared to unsubstituted compound MF1. Substitution phenyl ring in Compound MF1 by 2-pyridine/4-pyridine appeared to potentiate antimalarial activity and by Indole (compound MF5, IC50: 1.22 µg/ml) leads to a slight reduction in potency. Replacement of phenyl ring with a heterocyclic ring like Pyrrole (compound MF4, IC50: 1.14µg/ml) shows a moderate increase in an activity whereas in the case of Thiophen (compound MF7, IC50: 1.06 µg/ml) leads to significant increase in antimalarial activity.


There is an urgent need for discovery of new and effective antimalarial agents after widespread development of resistance to currently available antimalarial drugs. As part of our research, we have synthesized a series of ten 3-phenyl-2-thioxothiazolidin-4-one (MF1-MF10) derivatives, by Knoevenagel condensation of N-phenyl rhodanine (I1) with substituted aromatic or hetro aromatic aldehydes using microwave irradiation. After spectral confirmation, all the compounds were screened for invitro antimalarial activity against resistant strain of plasmodium falciparum. One compound MF9 showed most significant result with maximum activity (IC50 = 0.85µg/ml), thus it could be useful as a structural lead for future development of novel antimalarial molecules.


The authors are thankful to Director, S. G. S. I. T. S., Indore for providing facilities for successful completion of above work.


Authors have none to declare


  1. World Health Organization. World malaria report 2016. Geneva, Switzerland: World Health Organization. Available from: [Last accessed on 10 Oct 2016]
  2. Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL, Collins FH, et al. Malaria: progress, perils, and prospects for eradication. J Clin Invest 2008;118:1266-76.
  3. Trampuz A, Jereb M, Muzlovic I, Prabhu RM. Clinical review: severe malaria. Crit Care 2003;7:315-23.
  4. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discovery 2004;3:509-20.
  5. Severini C, Menegon M. Resistance to antimalarial drugs: an endless world war against Plasmodium that we risk losing. J Global Antimicrobial Resistance 2015;3:58-63.
  6. Sibley CH, Price RN. Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present. Int J Parasitol: Drugs Drug Resist 2012;2:126-33.
  7. AbdelKhalek A, Ashby CR Jr, Patel BA, Talele TT, Seleem MN. In vitro antibacterial activity of rhodanine derivatives against pathogenic clinical isolates. PLoS One 2016;11:e0164227.
  8. Liu J, Wu F, Chen L, Hu J, Zhao L, Chen C, et al. Evaluation of dihydropyrimidin-(2H)-one analogues and rhodanine derivatives as tyrosinase inhibitors. Bioorg Med Chem Lett 2011;21:2376-9.
  9. Kamila S, Ankati H, Biehl ER. An efficient microwave assisted synthesis of a novel class of Rhodanine derivatives as potential HIV-1 and JSP-1 inhibitors. Tetrahedron Lett 2011;52:4375-7.
  10. Ramkumar K, Yarovenko VN, Nikitina AS, Zavarzin IV, Krayushkin MM, Kovalenko LV, et al. Design, synthesis and structure-activity studies of rhodanine derivatives as HIV-1 integrase inhibitors. Molecules 2010;15:3958-92.
  11. Murugan R, Anbazhagan S, Lingeshwaran, Sriman Narayanan S. Synthesis and in vivo antidiabetic activity of novel dispiropyrrolidines through [3+2] cycloaddition reactions with a thiazolidinedione and rhodanine derivatives. Eur J Med Chem 2009;44:3272-9.
  12. Azizmohammadi M, Khoobi M, Ramazani A, Emami S, Zarrin A, Firuzi O, et al. 2H-chromene derivatives bearing thiazolidine-2,4-dione, rhodanine or hydantoin moieties as potential anticancer agents. Eur J Med Chem 2013;59:15-22.
  13. Kumar G, Parasuraman P, Sharma SK, Banerjee T, Karmodiya K, Surolia N, et al. Discovery of a rhodanine class of compounds as inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase. J Med Chem 2007;50:2665-75.
  14. Tomasic T, Masic LP. Rhodanine as a privileged scaffold in drug discovery. Curr Med Chem 2009;16:1596-629.
  15. Sing WT, Lee CL, Yeo SL, Lim SP, Sim MM. Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor. Bioorg Med Chem Lett 2001;11:91-4.
  16. Foley M, Tilley L. Quinoline antimalarials: mechanisms of action and resistance. Int J Parasitol 1997;27:231-40.

How to cite this article

  • Mehul Zaveri, Neha Kawathekar. Synthesis and antimalarial activity of some new 3-phenyl-2-thioxothiazolidin-4-one derivatives. Int J Curr Pharm Res 2017;9(3):58-61.

About this article




P. falciparum, 3-phenyl-2-thioxothiazolidin-4-one, Antimalarial activity





Additional Links

Manuscript Submission


International Journal of Current Pharmaceutical Research
Vol 9, Issue 3, 2017 Page: 58-61

Online ISSN


Authors & Affiliations

Mehul Zaveri
Department of Pharmacy, Shri G. S Institute of Technology and Science, 23-Park Road, Indore (MP) India 452003

Neha Kawathekar
Department of Pharmacy, Shri G. S Institute of Technology and Science, 23-Park Road, Indore (MP) India 452003


  • There are currently no refbacks.